ClinicalTrials.gg
RecruitingNCT04075305MOMENTUMUpdated Mar 5, 2026

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

An observational study in Oncology, Breast Cancer and Prostate Cancer, sponsored by UMC Utrecht. Recruiting at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by UMC Utrecht · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8,000
Ages
18 Years and older
Sex
All
01

Study summary

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Read the detailed description

Rationale: Radiation therapy has become indispensable in cancer treatment. However, it is associated with severe side effects. Innovation in radiation therapy has resulted in the development of MR-guided radiation therapy (MRGRT) which allows high precision radiotherapy under real time MR visualization. High precision MRGRT has the potential of dose escalation and margin reduction and may potentially lead to higher cure rates and less toxicity. MRGRT can be delivered by the MRI guided Linear Accelerator (MR-Linac) which integrates a state-of-the-art linear accelerator, 1.5T diagnostic quality MRI and an online adaptive workflow.

Objective: The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into clinical practice. In MOMENTUM, technical and clinical data are gathered in order to optimize software, evaluate treatment outcomes, toxicities and progression free, disease free, and overall survival per disease site, and create a repository of anatomical and biological MR sequences to develop new features.

Study design: A multi-institutional, international observational cohort study. Study population: Cancer patients ≥ 18 years receiving treatment and/or imaging on an MR-Linac machine are eligible for enrollment.

Main study parameters/endpoints: MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.

02

Conditions studied

  • Oncology
  • Breast Cancer
  • Prostate Cancer
  • Gynecologic Cancer
  • Brain Tumor
  • Brain Cancer
  • Gynecologic Tumor
  • Prostate Tumor
  • Prostate Neoplasm
  • Breast Tumor
  • Radiation Toxicity
  • Quality of Life
  • Rectal Cancer
  • Rectal Tumor
  • Rectal Neoplasms
  • Lung Cancer
  • Lung Tumor
  • Lung Neoplasm
  • Esophageal Cancer
  • Esophagus Cancer
  • Esophageal Tumor
  • Esophageal Neoplasm
  • Esophagus Tumor
  • Esophagus Neoplasm
  • Pancreatic Cancer
  • Pancreatic Tumor
  • Pancreatic Neoplasms
  • Head and Neck Cancer
  • Head and Neck Neoplasms
  • Head and Neck Tumor
  • Tumor
  • Neoplasms
  • Bladder Cancer
  • Bladder Neoplasm
  • Liver Cancer
  • Liver Neoplasms
  • Liver Metastases
  • Oligometastases
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 8,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

UMC Utrecht is the lead sponsor of 364 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving treatment and/or imaging on an MR-Linac machine are eligible for enrolment. Patients must meet eligibility criteria and provide informed consent to be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;
  • Patient provides written, ;
  • Patient is 18 years old or older.

Exclusion criteria

Exclusion Criteria:

  • MRI exclusion criteria, including
  • MRI as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Brain cancer

    Radiation: Radiation therapy

  • Lung cancer

    Radiation: Radiation therapy

  • Esophageal cancer

    Radiation: Radiation therapy

  • Breast Cancer

    Radiation: Radiation therapy

  • Head and Neck Cancer

    Radiation: Radiation therapy

  • Pancreatic cancer

    Radiation: Radiation therapy

  • Gynecological cancer

    Radiation: Radiation therapy

  • Rectal cancer

    Radiation: Radiation therapy

  • Prostate cancer

    Radiation: Radiation therapy

  • Bladder cancer

    Radiation: Radiation therapy

  • Oligometastases

    Radiation: Radiation therapy

  • Liver cancer

    Radiation: Radiation therapy

  • Other types of cancer

    Radiation: Radiation therapy

Interventions

  • RadiationRadiation therapy

    Radiation therapy on the CE marked and FDA approved MR-Linac

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 3 months after MR-Linac treatment

  2. Progression-free Survival

    Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 6 months after MR-Linac treatment

  3. Progression-free Survival

    Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 24 months after MR-Linac treatment

  4. Survival

    Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 3 months after MR-Linac treatment

  5. Survival

    Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 6 months after MR-Linac treatment

  6. Survival

    Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 24 months after MR-Linac treatment

  7. Disease-free Survival

    Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 3 months after MR-Linac treatment

  8. Disease-free Survival

    Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 6 months after MR-Linac treatment

  9. Disease-free Survival

    Disease-free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

    Time frame: 24 months after MR-Linac treatment

  10. Patient reported Health related quality of life (HRQoL).

    Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 3 months after treatment.

  11. Patient reported Health related quality of life (HRQoL).

    Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive, and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 6 months after treatment.

  12. Patient reported Health related quality of life (HRQoL).

    Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 12 months after treatment.

  13. Patient reported Health related quality of life (HRQoL).

    Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. They include 5 functional scales (physical, role, emotional, cognitive and social), three symptom scales, a global health scale, and six single items. All of these scales and items measures range in score from 0 to 100. A high score on functional or global health status scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 24 months after treatment.

  14. Patient reported Health related quality of life (HRQoL).

    Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'.

    Time frame: 3 months after treatment.

  15. Patient reported Health related quality of life (HRQoL).

    Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'.

    Time frame: 6 months after treatment.

  16. Patient reported Health related quality of life (HRQoL).

    Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'.

    Time frame: 12 months after treatment.

  17. Patient reported Health related quality of life (HRQoL).

    Generic patient reported quality of life is captured by The EuroQol (EQ)-5D-5L questionnaire. This includes a descriptive system questionnaire and visual analogue scale (VAS). The descriptive system scores five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) from 1 to 5 where 1 means having no problems, and 5 means extreme problems or unable to participate. The digits can be combined in a 5-digit code to describe the overall health status. For example, 12111. The VAS records the overall current health on a vertical visual analogue scale from 0 to 100, respectively 'the worst health you can imagine' to 'the best health you can imagine'.

    Time frame: 24 months after treatment.

  18. Patient reported tumor specific quality of life (QoL).

    Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 3 months after treatment.

  19. Patient reported tumor specific quality of life (QoL).

    Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 6 months after treatment.

  20. Patient reported tumor specific quality of life (QoL).

    Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 12 months after treatment.

  21. Patient reported tumor specific quality of life (QoL).

    Disease-specific patient reported quality of life is captured by a tumor specific EORTC QLQ questionnaire. (Brain-BN20, Breast-BR23, Bladder-BLM30, colorectal-CR29, Gynecological-CX24\&VU34, Head and Neck-HN35, liver-HCC18 (primary) and -LMC21 (metastasis), lung-LC13, esophageal-OES18, prostate-PR2, pancreas-PAN26). They all include a different set of functional scales and symptom scales. All of these scales and items measures range in score from 0 to 100. A high score on functional scale represents a high/healthy level of functioning. A high score for a symptom scale represents a high level of symptomatology.

    Time frame: 24 months after treatment.

  22. Acute toxicity in common toxicity criteria for adverse events (CTCAE).

    Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.

    Time frame: 3 months after treatment.

  23. Acute toxicity in common toxicity criteria for adverse events (CTCAE).

    Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.

    Time frame: 6 months after treatment.

  24. Acute toxicity in common toxicity criteria for adverse events (CTCAE).

    Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.

    Time frame: 12 months after treatment.

  25. Acute toxicity in common toxicity criteria for adverse events (CTCAE).

    Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary.

    Time frame: 24 months after treatment.

  26. Clinical tumor response.

    Clinical tumor response in participating patients is obtained from hospital information systems. Clinical patient follow-up and re-staging procedures are conducted to local standard of care practices.

    Time frame: 2 year follow up.

  27. Pathological tumor response.

    Pathological tumor response in participating patients who undergo surgery are obtained from hospital information systems. Clinical patient follow-up and re-staging procedures are conducted to local standard of care practices.

    Time frame: 2 year follow up.

  28. Toxicity in common toxicity criteria for adverse events (CTCAE).

    Disease-specific toxicity is obtained from the hospital information system.

    Time frame: 2 years

07

Study locations

14 of 18 sites recruiting
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Tom Colonias · Contact
  • Md Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • William A Hall · Contact
  • Austin Health - Olivia Newton-John Cancer Wellness and Research Centre
    Melbourne, Australia
    Not yet recruiting
    • Sweet Ping · Contact
  • Insitut Jules Bordet
    Brussels, Belgium
    Not yet recruiting
    • Robbe van den Begin · Contact
  • Sunnybrook Health Sciences Centre/Odette Cancer Centre
    Toronto, Ontario, Canada
    Recruiting
    • Arjun Sahgal · Contact
  • University Health Network - Princess Margaret Cancer Center
    Toronto, Canada
    Recruiting
    • Michael Velec · Contact
  • Odense Universitetshospital
    Odense, Funen 5000, Denmark
    Recruiting
  • Universitätsklinikum Tübingen
    Tübingen, Germany
    Recruiting
    • Cihan Gani · Contact
  • Università degli Studi di Brescia
    Brescia, Italy
    Not yet recruiting
    • Stefano Magrini · Contact
  • IRCCS Ospedale Sacro Cuore Don Calabria
    Negrar, Italy
    Recruiting
    • Filippo Alongi · Contact
  • Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital
    Amsterdam, Netherlands
    Recruiting
    • Marlies N Nowee · Contact
  • Radiotherapiegroep
    Deventer, Netherlands
    Recruiting
    • Paul Jeene · Contact
  • Radiotherapeutisch Instituut Friesland (RIF)
    Leeuwarden, Netherlands
    Not yet recruiting
    • Peter de Boer · Contact
  • Radboud UMC
    Nijmegen, Netherlands
    Recruiting
    • Linda Kerkmeijer · Contact
  • University Medical Center Utrecht
    Utrecht, 3508GA, Netherlands
    Recruiting
  • The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre
    London, United Kingdom
    Recruiting
    • Shaista Hafeez · Contact
  • The Christie National Health Service Foundation Trust
    Manchester, United Kingdom
    Recruiting
    • Ananya Choudhury · Contact
08

References and documents

Publications

  • Cooper S, Alexander S, Cherry C, Chick J, Dassen MG, Dunlop A, Hassan S, Herbert T, Mason F, Mitchell A, Nill S, Oelfke U, Pos F, Saifuddin M, Westley R, van der Heide UA, Vesprini D, Tree A. Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study. Radiother Oncol. 2026 Mar;216:111363. doi: 10.1016/j.radonc.2026.111363. Epub 2026 Jan 6. PubMed 41506574 ↗
  • Tan H, Stewart J, Ruschin M, Wang MH, Myrehaug S, Tseng CL, Detsky J, Husain Z, Chen H, Sahgal A, Soliman H. Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study. J Neurooncol. 2022 Feb;156(3):569-577. doi: 10.1007/s11060-021-03938-w. Epub 2022 Jan 3. PubMed 34981300 ↗
  • de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol. 2020 Sep 7;10:1328. doi: 10.3389/fonc.2020.01328. eCollection 2020. PubMed 33014774 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Feb 2030, 132 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 132 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2019
First posted
Aug 30, 2019
StartActual
Feb 1, 2019
Primary completionEst.
Feb 1, 2030
CompletionEst.
Aug 1, 2030
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04075305
Lead sponsor
UMC Utrecht
Collaborators
The Netherlands Cancer Institute, Sunnybrook Health Sciences Centre, M.D. Anderson Cancer Center, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Medical College of Wisconsin, Elekta Limited, Odense University Hospital, Radboud University Medical Center, Radiotherapiegroep, Jules Bordet Institute, University Hospital Tuebingen, Radiotherapeutic Institute Friesland, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), IRCCS Sacro Cuore Don Calabria di Negrar, Austin Health, Princess Margaret Hospital, Canada, Università degli Studi di Brescia
Responsible party
Helena M Verkooijen (Prof. Dr., UMC Utrecht) — Principal investigator
First posted
Aug 30, 2019
Start date
Feb 1, 2019
Primary completion
Feb 1, 2030 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Mar 5, 2026

Study contacts

Tessa Leer
Contact
T.Leer@umcutrecht.nl
T +31 (0)88 75 63707
Helena M Verkooijen, Prof, Dr
principal investigator · Universitair Medical Centre Utrecht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion